<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889898</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00016872</org_study_id>
    <nct_id>NCT04889898</nct_id>
  </id_info>
  <brief_title>Remote Speech and Swallowing Assessment in ALS</brief_title>
  <official_title>Home Telemonitoring of Bulbar Function by Acoustic Measurement of Swallowing and Speech Sounds in ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Congressionally Directed Medical Research Programs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a longitudinal home study of ALS patients to measure the severity&#xD;
      of speech and swallowing (bulbar) impairment via a smartphone-based, remote speech and&#xD;
      swallow assessment (rSSA). The study is designed to assess the feasibility and validity of&#xD;
      such a monitoring intervention. Furthermore, it is proposed that regular monitoring of these&#xD;
      two bulbar processes may shed light on their co-evolution over the course of ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most individuals with ALS experience bulbar function deterioration over the course of the&#xD;
      disease which impacts their quality of life significantly. Furthermore, in some patients,&#xD;
      bulbar symptoms are an initial presenting symptom of ALS. Identifying these changes, which&#xD;
      may be rapid in some individuals, is complicated by the recent acceleration of virtual care&#xD;
      delivery.&#xD;
&#xD;
      The investigators propose a longitudinal home study of ALS patients to assess bulbar&#xD;
      progression via a smartphone-based, self-administered remote speech and swallow assessment&#xD;
      (rSSA). The overall hypothesis is that this monitoring protocol can be used in a way that, 1)&#xD;
      is satisfactory to the patient, 2) performs at least as well as standard clinical measures of&#xD;
      dysarthria and dysphagia, and 3) resolves the development of emergence of speech and&#xD;
      swallowing pathologies in ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study involves two arms. Patients will be enrolled and participating study activities related to monitoring speech and swallow changes over 24 weeks. Listeners will also be enrolled to judge the intelligibility of the speech samples recorded by patients. 20 patients are anticipated to be enrolled and up to 150 listeners.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Digital recording of speech and swallow</measure>
    <time_frame>weekly for 24 weeks</time_frame>
    <description>Audio recordings of speech tasks and spontaneous swallowing task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MBS Impairment Profile (MBSImp)</measure>
    <time_frame>Weeks 0 and 24</time_frame>
    <description>Standardized scoring for the MBSS in 17 domains. Domains are aggregated in to scores for Oral Impairment (0-22), Pharyngeal Impairment (0-29), and Esophogeal Impairment (0-4), with higher scores indicating impaired function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speecch Intelligibility Task (SIT) Intelligibility listener scoring</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>Listeners will score the intelligibility of patient SIT recordings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALS Functional Rating Scale - Revised (ALSFRS-R)</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>ALS Specific Assessment of physical function ranging from 0-48, with 48 being normal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Center for Neurological Study - Bulbar Function Scale (CNS-BFS)</measure>
    <time_frame>Weeks 0, 4, 8, 12, 16, 20, and 24</time_frame>
    <description>Self-administered rating scale for speech (7-49) and salivation (7-35) functions, with high scores indicating impaired function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mann Assessment of Swallowing Ability (MASA)</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>A standard clinical swallowing assessment performed by the speech-language pathologist. Scores range from 38-200, with lower scores indicating higher impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EAT-10 Questionnaire</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>A self-reported assessment of eating and swallowing function. Scores range from 0-40, with higher scores indicating higher impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>A standard clinical respiratory assessment of vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Inspiratory Pressure (MIP)</measure>
    <time_frame>Weeks 0, 12, and 24</time_frame>
    <description>A standard clinical respiratory assessment of inspiratory strength</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>ALS Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Listeners</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone</intervention_name>
    <description>[Patients only] Weekly completion of audio recordings of speech and swallowing performed at home by the subject using the study smartphone application on their personal device.</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Modified Barium Swallow Study (MBSS)</intervention_name>
    <description>[Patients only] MBSS is an instrumented evaluation of oropharyngeal swallowing function that is performed using videofluoroscopy.</description>
    <arm_group_label>ALS Patients</arm_group_label>
    <other_name>Videofluoroscopic Swallowing Study (VFSS)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Speech Intelligibility Test (SIT)</intervention_name>
    <description>[Patients only] The SIT is a standardized test for measuring speech intelligibility.</description>
    <arm_group_label>ALS Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SIT Scoring</intervention_name>
    <description>[Listeners only] Listeners will judge the intelligibility of speech recordings made by patients in the study.</description>
    <arm_group_label>Listeners</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          1. At least 18 years of age&#xD;
&#xD;
          2. Possess a diagnosis of ALS (definite, probable, probable laboratory-supported, or&#xD;
             possible by El Escorial criteria [35])&#xD;
&#xD;
          3. Have symptom onset within the last 3 years&#xD;
&#xD;
          4. Demonstrate a score of 2 or 3 in either the speech (item #1) or swallowing (item #3)&#xD;
             components of the ALSFRS-R at time of enrollment&#xD;
&#xD;
          5. Demonstrate decline in bulbar function prior to enrollment, measured by a reduction of&#xD;
             at least 1 point on either the speech or swallowing components of the ALSFRS-R in the&#xD;
             6 months prior to enrollment. If 6 months of data is not available, an estimate of the&#xD;
             change in ALSFRS-R will be calculated from the time of symptom onset.&#xD;
&#xD;
          6. Have a life expectancy â‰¥ 6 months as determined by the attending neurologist&#xD;
&#xD;
          7. Be fluent in written and spoken English&#xD;
&#xD;
          8. Possess a smartphone capable of running the study application&#xD;
&#xD;
          9. Follow up in the Penn State Hershey multidisciplinary ALS clinic over next 6 months&#xD;
&#xD;
         10. Be able to visit the study site for in-person procedures at weeks 0 and 24&#xD;
&#xD;
        Listeners&#xD;
&#xD;
          1. Between 18 and 40 years of age&#xD;
&#xD;
          2. Native speakers of American English 2.3. Currently residing within the United States.&#xD;
             3.4. Hearing within normal limits, as defined by self report.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          1. Possess a co-existing neurological or psychiatric illness that, in the opinion of the&#xD;
             study team, exclude the subject from participation&#xD;
&#xD;
          2. Demonstrate clinically significant dementia, as determined by the ALS study&#xD;
             neurologist&#xD;
&#xD;
          3. Possess abnormal speech or swallowing processes due to a condition independent of&#xD;
             their ALS diagnosis&#xD;
&#xD;
        Listeners&#xD;
&#xD;
          1. Have an identified speech, language, learning, or neurological disorders per&#xD;
             self-report&#xD;
&#xD;
          2. Experience communicating with people with motor speech disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Geronimo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Geronimo, PhD</last_name>
    <phone>717-531-0003</phone>
    <phone_ext>282576</phone_ext>
    <email>ageronimo@pennstatehealth.psu.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Geronimo</investigator_full_name>
    <investigator_title>Assistant Professor, Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>telemonitoring</keyword>
  <keyword>digital health</keyword>
  <keyword>mobile health</keyword>
  <keyword>dysphagia</keyword>
  <keyword>dysarthria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

